Miriam E. Mossoba

611 total citations
29 papers, 425 citations indexed

About

Miriam E. Mossoba is a scholar working on Oncology, Pharmacology and Immunology. According to data from OpenAlex, Miriam E. Mossoba has authored 29 papers receiving a total of 425 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Pharmacology and 8 papers in Immunology. Recurrent topics in Miriam E. Mossoba's work include Drug-Induced Hepatotoxicity and Protection (7 papers), CAR-T cell therapy research (6 papers) and Immunotherapy and Immune Responses (6 papers). Miriam E. Mossoba is often cited by papers focused on Drug-Induced Hepatotoxicity and Protection (7 papers), CAR-T cell therapy research (6 papers) and Immunotherapy and Immune Responses (6 papers). Miriam E. Mossoba collaborates with scholars based in United States, Canada and India. Miriam E. Mossoba's co-authors include Jeffrey A. Medin, Robert L. Sprando, Shan Man, Urban Emmenegger, Robert S. Kerbel, Giulio Francia, Daniel J. Hicklin, Alicia Viloria‐Petit, Thomas J. Flynn and Daniel H. Fowler and has published in prestigious journals such as Blood, Clinical Cancer Research and Food and Chemical Toxicology.

In The Last Decade

Miriam E. Mossoba

28 papers receiving 420 citations

Peers

Miriam E. Mossoba
Mohd M. Khan United States
Khurum Khan United Kingdom
Jianxia Guo United States
Kimberly L. Moulton United States
Mauricio Leal United States
Miriam E. Mossoba
Citations per year, relative to Miriam E. Mossoba Miriam E. Mossoba (= 1×) peers Jinhua Wang

Countries citing papers authored by Miriam E. Mossoba

Since Specialization
Citations

This map shows the geographic impact of Miriam E. Mossoba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miriam E. Mossoba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miriam E. Mossoba more than expected).

Fields of papers citing papers by Miriam E. Mossoba

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miriam E. Mossoba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miriam E. Mossoba. The network helps show where Miriam E. Mossoba may publish in the future.

Co-authorship network of co-authors of Miriam E. Mossoba

This figure shows the co-authorship network connecting the top 25 collaborators of Miriam E. Mossoba. A scholar is included among the top collaborators of Miriam E. Mossoba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miriam E. Mossoba. Miriam E. Mossoba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mossoba, Miriam E., et al.. (2021). Evaluation of transporter expression in HK-2 cells after exposure to free and ester-bound 3-MCPD. Toxicology Reports. 8. 436–442. 4 indexed citations
2.
Araújo, Magali, Shaun MacMahon, Thomas J. Flynn, et al.. (2020). Assessment of intestinal absorption/metabolism of 3-chloro-1,2-propanediol (3-MCPD) and three 3-MCPD monoesters by Caco-2 cells. Toxicology in Vitro. 67. 104887–104887. 23 indexed citations
3.
Mossoba, Miriam E., Magali Araújo, Brenna M. Flannery, et al.. (2019). In vitro toxicological assessment of free 3-MCPD and select 3-MCPD esters on human proximal tubule HK-2 cells. Cell Biology and Toxicology. 36(3). 209–221. 24 indexed citations
4.
Araújo, Magali, et al.. (2019). A method to dissolve 3-MCPD mono- and di-esters in aqueous cell culture media. MethodsX. 7. 100774–100774. 6 indexed citations
5.
Mossoba, Miriam E., Vanessa Topping, Thomas Black, et al.. (2018). Diglycolic acid induces HepG2/C3A liver cell toxicity in vitro. Toxicology in Vitro. 52. 87–93. 5 indexed citations
6.
Mossoba, Miriam E., Vanessa Topping, Thomas Black, et al.. (2017). Comparison of diglycolic acid exposure to human proximal tubule cells in vitro and rat kidneys in vivo. Toxicology Reports. 4. 342–347. 6 indexed citations
7.
Sprando, Robert L., Miriam E. Mossoba, Thomas Black, et al.. (2017). 28-day repeated dose response study of diglycolic acid: Renal and hepatic effects. Food and Chemical Toxicology. 106(Pt A). 558–567. 12 indexed citations
8.
Mossoba, Miriam E., et al.. (2016). Nephrotoxicity of Combining 2-Phenethylamine and N, N -Dimethyl-β-Phenethylamine. 2(1). 49–55. 7 indexed citations
9.
Mossoba, Miriam E., et al.. (2015). Human kidney proximal tubule cells are vulnerable to the effects of Rauwolfia serpentina. Cell Biology and Toxicology. 31(6). 285–293. 7 indexed citations
10.
Mossoba, Miriam E., et al.. (2015). In vitro exposure of Adhatoda zeylanica to human renal cells lacks acute toxicity. Toxicology Reports. 3. 15–20. 2 indexed citations
11.
Castiello, Luciano, Miriam E. Mossoba, Marianna Sabatino, et al.. (2013). Differential gene expression profile of first-generation and second-generation rapamycin-resistant allogeneic T cells. Cytotherapy. 15(5). 598–609. 2 indexed citations
12.
Hardy, Nancy M., Miriam E. Mossoba, Seth M. Steinberg, et al.. (2011). Phase I Trial of Adoptive Cell Transfer with Mixed-Profile Type-I/Type-II Allogeneic T Cells for Metastatic Breast Cancer. Clinical Cancer Research. 17(21). 6878–6887. 12 indexed citations
13.
Mossoba, Miriam E., Masanori Onda, Justin J. Taylor, et al.. (2011). Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts. Clinical Cancer Research. 17(11). 3697–3705. 36 indexed citations
14.
Mariotti, Jacopo, Justin J. Taylor, Paul R. Massey, et al.. (2010). The Pentostatin Plus Cyclophosphamide Nonmyeloablative Regimen Induces Durable Host T Cell Functional Deficits and Prevents Murine Marrow Allograft Rejection. Biology of Blood and Marrow Transplantation. 17(5). 620–631. 14 indexed citations
15.
Francia, Giulio, Shan Man, Christina R. Lee, et al.. (2009). Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2–Positive Human Breast Cancer Xenografts. Clinical Cancer Research. 15(20). 6358–6366. 33 indexed citations
16.
Francia, Giulio, Urban Emmenegger, Christina R. Lee, et al.. (2008). Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using β-human choriogonadotropin secreting tumor cell lines. Molecular Cancer Therapeutics. 7(10). 3452–3459. 21 indexed citations
17.
Mossoba, Miriam E., Jagdeep S. Walia, Renee Head, et al.. (2008). Tumor Protection Following Vaccination With Low Doses of Lentivirally Transduced DCs Expressing the Self-antigen erbB2. Molecular Therapy. 16(3). 607–617. 22 indexed citations
18.
19.
Mossoba, Miriam E., et al.. (2006). Using PCR amplification to increase the confidence level of Salmonella typhimurium DNA microarray chip hybridization. Molecular and Cellular Probes. 20(3-4). 163–171. 10 indexed citations
20.
Francia, Giulio, Shan Man, Miriam E. Mossoba, et al.. (2006). Strategies for Delaying or TreatingIn vivoAcquired Resistance to Trastuzumab in Human Breast Cancer Xenografts. Clinical Cancer Research. 12(3). 904–916. 116 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026